
### [NCIT:C3517](http://purl.obolibrary.org/obo/NCIT_C3517)
**Label:** Mixed Cellularity Classical Hodgkin Lymphoma

**Subclasses:** [NCIT:C8063](http://purl.obolibrary.org/obo/NCIT_C8063) (Childhood Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C8834](http://purl.obolibrary.org/obo/NCIT_C8834) (Stage I Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C8835](http://purl.obolibrary.org/obo/NCIT_C8835) (Stage IV Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C8832](http://purl.obolibrary.org/obo/NCIT_C8832) (Recurrent Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C8833](http://purl.obolibrary.org/obo/NCIT_C8833) (Refractory Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C9127](http://purl.obolibrary.org/obo/NCIT_C9127) (Adult Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C5077](http://purl.obolibrary.org/obo/NCIT_C5077) (Stage II Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C3582](http://purl.obolibrary.org/obo/NCIT_C3582) (Stage III Mixed Cellularity Classical Hodgkin Lymphoma), 

**Class expressions from DL-Learner:**

- Thing 54.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40187](http://purl.obolibrary.org/obo/NCIT_C40187) (Cervical Keratinizing Squamous Cell Carcinoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40182](http://purl.obolibrary.org/obo/NCIT_C40182) (Uterine Corpus Carcinofibroma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40177](http://purl.obolibrary.org/obo/NCIT_C40177) (Uterine Corpus Smooth Muscle Tumor of Uncertain Malignant Potential))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40175](http://purl.obolibrary.org/obo/NCIT_C40175) (Uterine Corpus Myxoid Leiomyosarcoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40174](http://purl.obolibrary.org/obo/NCIT_C40174) (Uterine Corpus Epithelioid Leiomyosarcoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40170](http://purl.obolibrary.org/obo/NCIT_C40170) (Uterine Corpus Diffuse Leiomyomatosis))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40168](http://purl.obolibrary.org/obo/NCIT_C40168) (Uterine Corpus Lipoleiomyoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40167](http://purl.obolibrary.org/obo/NCIT_C40167) (Uterine Corpus Bizarre Leiomyoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40166](http://purl.obolibrary.org/obo/NCIT_C40166) (Uterine Corpus Myxoid Leiomyoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40165](http://purl.obolibrary.org/obo/NCIT_C40165) (Uterine Corpus Apoplectic Leiomyoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40164](http://purl.obolibrary.org/obo/NCIT_C40164) (Uterine Corpus Epithelioid Leiomyoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40163](http://purl.obolibrary.org/obo/NCIT_C40163) (Uterine Corpus Cellular Leiomyoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40162](http://purl.obolibrary.org/obo/NCIT_C40162) (Uterine Corpus Leiomyoma, Mitotically Active Variant))) 36.78%


